{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:02:05Z","timestamp":1790820125691,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 A008748"],"award-info":[{"award-number":["P30 A008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtha.2025.06.030","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:52:12Z","timestamp":1752681132000},"page":"3286-3294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Venous thromboembolism in patients with cancer and factor XI deficiency"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5107-8340","authenticated-orcid":false,"given":"Pavlina","family":"Chrysafi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Xirou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maly","family":"Fenelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushad","family":"Patell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Zwicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-345X","authenticated-orcid":false,"given":"Avi","family":"Leader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.06.030_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jtha.2025.06.030_bib2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer-associated venous thromboembolism: Burden, mechanisms, and management","volume":"117","author":"Ay","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.030_bib3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtha.2025.06.030_bib4","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtha.2025.06.030_bib5","article-title":"Update on guidelines for the prevention of cancer-associated thrombosis","volume":"20","author":"Elshoury","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jtha.2025.06.030_bib6","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.06.030_bib7","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004118","article-title":"Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis","volume":"5","author":"Osataphan","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.06.030_bib8","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.2019001605","article-title":"How I assess and manage the risk of bleeding in patients treated for venous thromboembolism","volume":"135","author":"Klok","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.030_bib9","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1002\/onco.13584","article-title":"Treatment of cancer-associated venous thromboembolism with low-molecular-weight heparin or direct oral anticoagulants: patient selection, controversies, and caveats","volume":"26","author":"O'Connell","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.jtha.2025.06.030_bib10","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1182\/blood.2024025362","article-title":"Bleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort study","volume":"144","author":"Englisch","year":"2024","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.jtha.2025.06.030_bib11","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0049-3848(16)30354-1","article-title":"The hemostatic role of factor XI","volume":"141","author":"Puy","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.06.030_bib12","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/jth.12435","article-title":"Evidence for factor IX-independent roles for factor XIa in blood coagulation","volume":"11","author":"Matafonov","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.030_bib13","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/jth.12295","article-title":"Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates","volume":"11","author":"Puy","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.030_bib14","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1055\/s-0041-1735971","article-title":"The association between factor XI deficiency and the risk of bleeding, cardiovascular, and venous thromboembolic events","volume":"122","author":"Sharman Moser","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.030_bib15","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.030_bib16","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.3324\/haematol.2023.283682","article-title":"Novel horizons in anticoagulation: the emerging role of factor XI inhibitors across different settings","volume":"109","author":"Cohen","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2025.06.030_bib17","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/jth.13009","article-title":"Venous thrombosis and cancer: from mouse models to clinical trials","volume":"13","author":"Hisada","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.030_bib18","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood-2013-04-460139","article-title":"Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients","volume":"122","author":"Geddings","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.030_bib19","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1158\/1078-0432.CCR-09-0371","article-title":"Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy","volume":"15","author":"Zwicker","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtha.2025.06.030_bib20","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41416-022-01968-3","article-title":"Tissue factor in cancer-associated thromboembolism: possible mechanisms and clinical applications","volume":"127","author":"Koizume","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtha.2025.06.030_bib21","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00262-020-02739-w","article-title":"A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment","volume":"70","author":"Saidak","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtha.2025.06.030_bib22","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1182\/bloodadvances.2022008648","article-title":"Obstetric and perioperative management of patients with factor XI deficiency: a retrospective observational study","volume":"7","author":"Handa","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.06.030_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-222434","article-title":"Successful perioperative management in a patient with factor XI deficiency","volume":"2018","author":"McCarthy","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jtha.2025.06.030_bib24","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.030_bib25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.030_bib26","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2141.1988.tb02409.x","article-title":"Inheritance and bleeding in factor XI deficiency","volume":"69","author":"Bolton-Maggs","year":"1988","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.06.030_bib27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-0044-1792033","article-title":"Laboratory and molecular diagnosis of factor XI deficiency","volume":"51","author":"Davidson","year":"2025","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.06.030_bib28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/MBC.0000000000001287","article-title":"In vitro differential inhibition of the factor XI activity assay in the setting of a lupus anticoagulant","volume":"35","author":"Rabichow","year":"2024","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2025.06.030_bib29","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.030_bib30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.030_bib31","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1214\/aos\/1176344198","article-title":"Nonparametric estimation of partial transition probabilities in multiple decrement models","volume":"6","author":"Aalen","year":"1978","journal-title":"Ann Statist"},{"key":"10.1016\/j.jtha.2025.06.030_bib32","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.030_bib33","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.030_bib34","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.06.030_bib35","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"Buller","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.030_bib36","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1111\/jth.15890","article-title":"Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery\u2014systematic review and meta-analysis","volume":"20","author":"Presume","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.030_bib37","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41591-023-02794-7","article-title":"Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial","volume":"30","author":"Weitz","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2025.06.030_bib38","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","article-title":"Phase 2 study of the factor XI antisense inhibitor IONIS-FXI(Rx) in patients with ESRD","volume":"7","author":"Walsh","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jtha.2025.06.030_bib39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jtha.2023.09.015","article-title":"Effect of factor XI inhibition on tumor cell-induced coagulation activation","volume":"22","author":"M\u00e4der","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.030_bib40","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/oncolo\/oyad116","article-title":"Treatment of cancer-associated thrombosis: recent advances, unmet needs, and future direction","volume":"28","author":"Wang","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.jtha.2025.06.030_bib41","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/ATVBAHA.123.319692","article-title":"Factor XI inhibition for the prevention of catheter-associated thrombosis in patients with cancer undergoing central line placement: a phase 2 clinical trial","volume":"44","author":"Pfeffer","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2025.06.030_bib42","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.thromres.2017.10.008","article-title":"An update on factor XI structure and function","volume":"161","author":"Mohammed","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.06.030_bib43","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood.2023020721","article-title":"Factor XI deficiency: phenotypic age-related considerations and clinical approach towards bleeding risk assessment","volume":"143","author":"Barg","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.030_bib44","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus rivaroxaban in patients with atrial fibrillation","volume":"392","author":"Ruff","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.030_bib45","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2516.2006.01304.x","article-title":"Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy","volume":"12","author":"Salomon","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.06.030_bib46","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1055\/s-0039-1692439","article-title":"The safety and efficacy of novel agents targeting factors XI and XII in early phase human trials","volume":"45","author":"DeLoughery","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.06.030_bib47","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/jth.15579","article-title":"A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors","volume":"20","author":"Salomon","year":"2022","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625004192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625004192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:24:31Z","timestamp":1790817871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625004192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1538783625004192"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.030","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venous thromboembolism in patients with cancer and factor XI deficiency","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}